Logo image of ALIM

ALIMERA SCIENCES INC (ALIM) Stock Fundamental Analysis

USA - NASDAQ:ALIM - US0162592028 - Common Stock

5.54 USD
-0.01 (-0.18%)
Last: 9/13/2024, 8:00:00 PM
5.54 USD
0 (0%)
After Hours: 9/13/2024, 8:00:00 PM
Fundamental Rating

4

Overall ALIM gets a fundamental rating of 4 out of 10. We evaluated ALIM against 196 industry peers in the Pharmaceuticals industry. ALIM may be in some trouble as it scores bad on both profitability and health. ALIM shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ALIM has reported negative net income.
ALIM had a negative operating cash flow in the past year.
In the past 5 years ALIM always reported negative net income.
ALIM had a negative operating cash flow in each of the past 5 years.
ALIM Yearly Net Income VS EBIT VS OCF VS FCFALIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M

1.2 Ratios

ALIM has a better Return On Assets (-10.16%) than 72.82% of its industry peers.
With a decent Return On Equity value of -39.38%, ALIM is doing good in the industry, outperforming 62.05% of the companies in the same industry.
With a decent Return On Invested Capital value of 0.12%, ALIM is doing good in the industry, outperforming 76.92% of the companies in the same industry.
Industry RankSector Rank
ROA -10.16%
ROE -39.38%
ROIC 0.12%
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALIM Yearly ROA, ROE, ROICALIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 400 600 800

1.3 Margins

ALIM has a better Operating Margin (0.20%) than 76.92% of its industry peers.
ALIM has a better Gross Margin (86.39%) than 90.26% of its industry peers.
In the last couple of years the Gross Margin of ALIM has remained more or less at the same level.
Industry RankSector Rank
OM 0.2%
PM (TTM) N/A
GM 86.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
ALIM Yearly Profit, Operating, Gross MarginsALIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

ALIM has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, ALIM has more shares outstanding
The number of shares outstanding for ALIM has been increased compared to 5 years ago.
The debt/assets ratio for ALIM has been reduced compared to a year ago.
ALIM Yearly Shares OutstandingALIM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
ALIM Yearly Total Debt VS Total AssetsALIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -1.37, we must say that ALIM is in the distress zone and has some risk of bankruptcy.
ALIM has a Altman-Z score (-1.37) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.80 is on the high side and indicates that ALIM has dependencies on debt financing.
The Debt to Equity ratio of ALIM (1.80) is worse than 78.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF N/A
Altman-Z -1.37
ROIC/WACC0.01
WACC9.95%
ALIM Yearly LT Debt VS Equity VS FCFALIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

A Current Ratio of 2.79 indicates that ALIM has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.79, ALIM is in line with its industry, outperforming 45.13% of the companies in the same industry.
ALIM has a Quick Ratio of 2.62. This indicates that ALIM is financially healthy and has no problem in meeting its short term obligations.
ALIM has a Quick ratio (2.62) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.62
ALIM Yearly Current Assets VS Current LiabilitesALIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.66% over the past year.
Looking at the last year, ALIM shows a very strong growth in Revenue. The Revenue has grown by 69.76%.
ALIM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.62% yearly.
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%

3.2 Future

Based on estimates for the next years, ALIM will show a very strong growth in Earnings Per Share. The EPS will grow by 22.30% on average per year.
The Revenue is expected to grow by 23.81% on average over the next years. This is a very strong growth
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALIM Yearly Revenue VS EstimatesALIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
ALIM Yearly EPS VS EstimatesALIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALIM. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 28.59, the valuation of ALIM can be described as expensive.
ALIM's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ALIM is cheaper than 77.44% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ALIM to the average of the S&P500 Index (22.71), we can say ALIM is valued slightly more expensively.
Industry RankSector Rank
PE N/A
Fwd PE 28.59
ALIM Price Earnings VS Forward Price EarningsALIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALIM indicates a somewhat cheap valuation: ALIM is cheaper than 77.95% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 28.66
ALIM Per share dataALIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

ALIM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALIM's earnings are expected to grow with 30.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.56%
EPS Next 3Y30.12%

More info and screens

0

5. Dividend

5.1 Amount

ALIM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALIMERA SCIENCES INC

NASDAQ:ALIM (9/13/2024, 8:00:00 PM)

After market: 5.54 0 (0%)

5.54

-0.01 (-0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2024-08-06/bmo
Earnings (Next)10-24 2024-10-24/amc
Inst Owners0.2%
Inst Owner Change0%
Ins Owners30.17%
Ins Owner Change0%
Market Cap301.27M
Analysts48.89
Price Target5.78 (4.33%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-84.01%
Min EPS beat(2)-107.6%
Max EPS beat(2)-60.41%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.13%
Min Revenue beat(2)1.39%
Max Revenue beat(2)2.87%
Revenue beat(4)4
Avg Revenue beat(4)2.76%
Min Revenue beat(4)0.83%
Max Revenue beat(4)5.96%
Revenue beat(8)5
Avg Revenue beat(8)-1.87%
Revenue beat(12)7
Avg Revenue beat(12)-1.43%
Revenue beat(16)10
Avg Revenue beat(16)1.21%
PT rev (1m)0%
PT rev (3m)-29.17%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.26%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 28.59
P/S 3.02
P/FCF N/A
P/OCF N/A
P/B 7.77
P/tB N/A
EV/EBITDA 28.66
EPS(TTM)-0.31
EYN/A
EPS(NY)0.19
Fwd EY3.5%
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS1.83
BVpS0.71
TBVpS-0.97
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.16%
ROE -39.38%
ROCE 0.15%
ROIC 0.12%
ROICexc 0.13%
ROICexgc 0.56%
OM 0.2%
PM (TTM) N/A
GM 86.39%
FCFM N/A
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
F-Score4
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 1.8
Debt/FCF N/A
Debt/EBITDA 5.55
Cap/Depr 1.81%
Cap/Sales 0.22%
Interest Coverage 0.03
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.62
Altman-Z -1.37
F-Score4
WACC9.95%
ROIC/WACC0.01
Cap/Depr(3y)299.05%
Cap/Depr(5y)185.34%
Cap/Sales(3y)31.69%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.45%
EPS Next Y94.02%
EPS Next 2Y44.56%
EPS Next 3Y30.12%
EPS Next 5Y22.31%
Revenue 1Y (TTM)69.76%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Sales Q2Q%53.95%
Revenue Next Year34.43%
Revenue Next 2Y23.92%
Revenue Next 3Y19.9%
Revenue Next 5Y23.81%
EBIT growth 1Y101.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3584.36%
EBIT Next 3Y329.62%
EBIT Next 5Y187.7%
FCF growth 1Y62.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.27%
OCF growth 3YN/A
OCF growth 5YN/A